Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Journal article
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
Diagnosing Diamond-Blackfan anaemia: 'vorsprung durch technik'.
Journal article
Hills RK., (2021), Br J Haematol
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Journal article
Dennis M. et al, (2021), Br J Haematol
Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
Journal article
Linch DC. et al, (2021), Leuk Res
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Journal article
Kayser S. et al, (2021), Br J Haematol, 192, 832 - 842
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Journal article
Burnett AK. et al, (2020), J Clin Oncol
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Journal article
Zabkiewicz J. et al, (2020), Br J Haematol
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
Journal article
Linch DC. et al, (2020), Br J Haematol, 188, 852 - 859
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Journal article
Dillon R. et al, (2020), Blood, 135, 680 - 688
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
Journal article
Linch DC. et al, (2020), Br J Haematol
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
Journal article
Hills RK., (2020), Br J Haematol, 188, 29 - 35
Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
Journal article
Burnett AK. et al, (2020), Br J Haematol, 188, 86 - 100
Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL.
Journal article
Elston L. et al, (2019), Br J Haematol
Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.
Journal article
Sasca D. et al, (2019), Blood
Mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Conference paper
Eiring AM. et al, (2019), CANCER RESEARCH, 79
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Journal article
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Journal article
Marquis M. et al, (2019), Blood Cancer J, 9
Real world data and the art of maintenance therapy.
Other
Hills RK., (2019), Br J Haematol, 184, 493 - 494
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Journal article
Burnett AK. et al, (2018), Leukemia, 32, 2693 - 2714
Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials
Conference paper
Hills RK. et al, (2018), BLOOD, 132